Spots Global Cancer Trial Database for azd6244
Every month we try and update this database with for azd6244 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | NCT00372944 | Pancreatic Canc... | AZD6244 capecitabine | 18 Years - | AstraZeneca | |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | NCT03004105 | Malignant Neopl... Advanced Lung C... Recurrent Nonsm... | Selumetinib Durvalumab Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Efficacy Study of AZD6244 in Colorectal Cancer | NCT00514761 | Metastatic Colo... | AZD6244 Capecitabine | 18 Years - | AstraZeneca | |
| A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | NCT02322749 | Healthy Volunte... | selumetinib 75m... selumetinib 75m... selumetinib 75m... | 18 Years - 45 Years | AstraZeneca | |
| AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen | NCT00372788 | Non-small Cell ... | AZD6244 Pemetrexed | 18 Years - | AstraZeneca | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150 | Non Small Cell ... | AZD6244 Erlotinib AZD6244 + Erlot... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 | NCT00970359 | Thyroid Cancer | AZD6244 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | NCT01306045 | Carcinoma, Non-... Carcinoma, Smal... Carcinoma, Thym... | AZD6244 MK-2206 Lapatinib Erlotinib Sunitinib Molecular Profi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | NCT01248247 | Lung Cancer | Erlotinib AZD6244 MK-2206 Sorafenib Erlotinib MK-2206 | 18 Years - | M.D. Anderson Cancer Center | |
| AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer | NCT01287130 | Colonic Neoplas... Cancer of the C... Colon Cancer Colon Neoplasms Colonic Cancer | Cetuximab AZD6244 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies | NCT00710515 | Melanoma Malignant Melan... | AZD6244 | 18 Years - | AstraZeneca | |
| Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | NCT00338130 | Melanoma | AZD6244 Temozolomide | 18 Years - | AstraZeneca | |
| AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | NCT00890825 | Non Small Cell ... | AZD6244 docetaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | NCT01134601 | Non-Metastatic ... | Radiation Thera... Capecitabine AZD6244 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150 | Non Small Cell ... | AZD6244 Erlotinib AZD6244 + Erlot... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | NCT01160926 | Rectal Cancer | AZD6244 Cediranib (AZD2... | 18 Years - | The Christie NHS Foundation Trust | |
| A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | NCT02322749 | Healthy Volunte... | selumetinib 75m... selumetinib 75m... selumetinib 75m... | 18 Years - 45 Years | AstraZeneca | |
| Selumetinib and Olaparib in Solid Tumors | NCT03162627 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Selumetinib Olaparib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | NCT01116271 | Colorectal Canc... | AZD6244 Irinotecan | 18 Years - | AstraZeneca | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | NCT01134601 | Non-Metastatic ... | Radiation Thera... Capecitabine AZD6244 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Personalized Treatment Selection for Metastatic Breast Cancer | NCT00780676 | Breast Cancer | Dasatinib AZD6244 | 18 Years - | M.D. Anderson Cancer Center | |
| Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | NCT00936221 | Melanoma | AZD6244 Dacarbazine Placebo | 18 Years - 130 Years | AstraZeneca | |
| MEK Inhibitor and Thoracic Radiotherapy Trial | NCT01146756 | Non Small Cell ... | AZD6244 | 18 Years - | The Christie NHS Foundation Trust | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers. | NCT02238782 | Healthy Volunte... | selumetinib 75m... [14C] selumetin... | 18 Years - 65 Years | AstraZeneca | |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | NCT00372944 | Pancreatic Canc... | AZD6244 capecitabine | 18 Years - | AstraZeneca | |
| Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 | NCT00970359 | Thyroid Cancer | AZD6244 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | NCT00338130 | Melanoma | AZD6244 Temozolomide | 18 Years - | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
